Pharmacy

In a global restructuring effort, Swiss drug giant Novartis will cut more than 2,000 jobs, according to The Wall Street Journal.

Gilead Sciences will offer a cheaper version of its blockbuster hepatitis C drugs, Epclusa and Harvoni, which sparked controversy when they were initially introduced at a price of more than $1,000 per pill, according to Bloomberg.

The Pharmaceutical Care Management Association, a lobbying group representing pharmacy benefit managers, has named JC Scott president and CEO, effective Oct. 15.

AbbVie was sued by the California Department of Insurance for allegedly orchestrating a wide-ranging kickback scheme to illegally boost prescriptions of its best-selling arthritis drug Humira, according to a STAT news report. 

Many drug companies questioned whether they should shutter operations at their drug plants in the Carolinas and Virginia during Hurricane Florence, which would put the region's drug supply at risk, according to STAT.

Amid a shortage, drug prices increase at roughly twice their usual rate, suggesting that pharma companies may be exploiting drug shortages to increase profits, according to a new study published in the Annals of Internal Medicine.

In an effort to save its reputation from the hit it took earlier this year, Swiss pharmaceutical giant Novartis revealed its employees will only get bonuses if they meet or exceed expectations for ethical behavior, according to Reuters.

The FDA found a second toxin that may cause cancer in three lots of valsartan, a commonly prescribed drug to control blood pressure and prevent heart failure.

Data is valuable currency to your biopharmaceutical company. It can tell you how well your new specialty drug is working for patients—and point out ways to make it work even better.

Bayer AG and Sanofi, two drugmakers based in Europe, will swap top executives, according to Reuters.